Ergomed plc provides update on co-development partnerships
18 September 2014 | By Issued by Hume Brophy on behalf of Ergomed
Good progress with partnerships and additional clinical studies commenced...
List view / Grid view
News
MSD presents first Phase 3 data in Japanese patients for Omarigliptin, an investigational once-weekly DPP-4 inhibitor for Type 2 Diabetes Omarigliptin significantly reduced HbA1c levels compared to placebo
18 September 2014 | By Merck
MSD, known as Merck & Co., Inc. in the United States and Canada, announced the presentation of the first data from the Phase 3 clinical development programme for omarigliptin, MSD’s investigational treatment for type 2 diabetes...
Ample room available for novel products in metastatic prostate cancer treatment market, says GlobalData Analyst
18 September 2014 | By Globaldata
Despite numerous product launches in the metastatic castration-resistant prostate cancer treatment market since 2010, ample opportunity still exists for drug developers to claim their stake in the arena...
Roche investing in Kaiseraugst
18 September 2014 | By Roche
Roche announced that it is planning to invest more than half a billion Swiss francs in buildings and infrastructure projects at Kaiseraugst...
Top 5 pharma company receives FDA validation using TranSEND by PDS
17 September 2014 | By PDS
PDS announces that a top 5 pharma company has used TranSEND™ to successfully submit multiple SEND datasets derived from different data sources to the Food and Drug Administration...
Moberg Pharma announces successful results for MOB-015 in a Phase II study for the treatment of onychomycosis
17 September 2014 | By Moberg Pharma
Moberg Pharma AB announces successful top-line results from a phase II study for MOB-015 in onychomycosis (nail fungus)...
European diabetes care has developed, saving 10 000 lives every year – but speedy improvement critical to meet the growth of diabetes, shows new EU comparison
17 September 2014 | By Health Consumer Powerhouse
Diabetes care in Europe makes progress, as shown by a European comparison of diabetes prevention and treatment presented today during the 50th Congress of the European Association for the Study of Diabetes (EASD) in Vienna...
Roche to present latest oncology advances during ESMO 2014 Congress
17 September 2014 | By Roche
Roche announced that important new data from its established and pipeline medicine portfolio will be presented during the European Society for Medical Oncology (ESMO) 2014 Congress from 26-30 September in Madrid, Spain...
FDA approves MOVANTIK™ (naloxegol) tablets C-II for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain
17 September 2014 | By AstraZeneca
AstraZeneca announced that the US Food and Drug Administration approved MOVANTIK™ (naloxegol) tablets C-II as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain...
Brintellix is launched as the first new antidepressant drug in five years in Denmark
16 September 2014 | By Lundbeck
...and will be introduced in several other European and International Markets during 2014 and 2015.
Bristol-Myers Squibb to challenge Merck in skin cancer treatment arena, says GlobalData Analyst
16 September 2014 | By GlobalData
Merck’s Keytruda, which was recently approved in the US to treat patients with advanced melanoma, who have stopped responding to other cancer therapies, will soon face strong competition from Bristol-Myers Squibb’s Opdivo, says an analyst with research and consulting firm GlobalData...
Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study
16 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company presented results from a 52-week Phase III study that demonstrated sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with Type 2 Diabetes...
BGI and The Vancouver Prostate Centre announce partnership to create Joint Research Laboratory for advancement of translational cancer research
16 September 2014 | By Alto Marketing Limited
BGI and The Vancouver Prostate Centre announced the establishment of the BGI-VPC Joint Research Laboratory, a sequencing and translational research facility, to jointly discover and advance basic and translational programs in oncology, including personalized oncology...
Cardio3 Biosciences receives approval for the continuation of its chart-1 Phase iii clinical trial from the DSMB
16 September 2014 | By Cardio3 BioSciences
Cardio3 BioSciences SA announces it has received the recommendation of the Data Safety and Monitoring Board (DSMB) to continue the CHART-1 clinical trial according to the original protocol...
Dolomite to launch Meros TCU-100 temperature controller at Lab-on-a-Chip & Microarray World Congress
16 September 2014 | By kdm communications
Microfluidics specialist Dolomite will be launching the Meros TCU-100 at this year’s Lab-on-a-Chip & Microarray World Congress in San Diego, USA, from the 18th to the 19th September...
